Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pruvanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pruvanserin SCHEMBL9104227 | 1.00 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL29379046 | 1.00 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL678953 | 0.99 | HTR2A (0.98) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL29489913 | 0.99 | HTR2A (0.98) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL3902103 | 0.96 | HTR2A (0.93) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL3914362 | 0.96 | HTR2A (0.93) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL6110393 | 0.91 | HTR2A (0.84) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL5280317 | 0.91 | HTR2A (0.84) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL6112038 | 0.91 | HTR2A (0.83) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL5925660 | 0.87 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630102-B1 | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | GLYTECH LLC (US) | 2024-08-14 | — | — | EP | claimed |
| US-11969431-B2 | Formulations for treatment of post-traumatic stress disorder | GLYTECH LLC (US) | 2024-04-30 | — | — | US | claimed |
| US-20230201193-A1 | COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS | GLYTECH LLC (US) | 2023-06-29 | — | — | US | claimed |
| US-20220252611-A1 | METHODS FOR USING MASS SPECTROSCOPY IN MULTIPLEX TARGET EVALUATIONS | EUROFINS CEREP (FR) | 2022-08-11 | — | — | US | claimed |
| EP-3973298-A1 | METHODS FOR USING MASS SPECTROSCOPY IN MULTIPLEX TARGET EVALUATIONS | Eurofins Cerep (FR) | 2022-03-30 | — | — | EP | claimed |
| EP-1794121-B1 | NOVEL CRYSTALLINE FORM OF (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)-PIPERAZINE-1-YL]-METHANONE HYDROCHLORIDE | MERCK PATENT GMBH (DE) | 2013-12-25 | — | — | EP | claimed |
| CN-101437793-B | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate | MERCK PATENT GMBH | 2012-08-22 | — | — | CN | claimed |
| EP-2016052-B1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | claimed |
| US-7981897-B2 | Crystal form of (3-cyano-1H-Indo1-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride | MERCK PATENT GMBH (DE) | 2011-07-19 | — | — | US | claimed |
| CN-101027284-B | Novel crystalline form of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanone hydrochloride | MERCK PATENT GMBH | 2010-09-29 | — | — | CN | claimed |
| CN-1589147-A | Use of N-(indolecarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-03-02 | — | — | CN | claimed |
| US-20050014766-A1 | Use of n-(indolecarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-6838461-B1 | N-(indolcarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-01-04 | — | — | US | claimed |
| EP-1198453-B9 | N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-11-10 | — | — | EP | claimed |
| EP-1353906-B1 | PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF | MERCK PATENT GMBH (DE) | 2004-06-23 | — | — | EP | claimed |
| CN-1487923-A | Process for the preparation of (3-cyano-1H-indol-7-yl) (4- (4-fluorophenethyl) piperazin-1-yl) -methanone and salts thereof | Ĭ��ר���ɷ�����˾ | 2004-04-07 | — | — | CN | claimed |
| US-20040063723-A1 | Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)- methanone and salts thereof | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | claimed |
| EP-1353906-A1 | PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF | MERCK PATENT GmbH (DE) | 2003-10-22 | — | — | EP | claimed |
| EP-1198453-B1 | N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-04-09 | — | — | EP | claimed |
| WO-2002059092-A1 | PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF | MERCK PATENT GMBH (DE) | 2002-08-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014766-A1 | Use of n-(indolecarbonyl-)piperazine derivatives | GPR119, CHRM1, HTR1A | HTR2A 11/4885HTR2C 5/4885DRD4 46/4885 |
| US-20040063723-A1 | Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)- methanone and salts thereof | TPH1, TPH2, IDO1 | HTR2A 32/4885HTR2C 15/4885DRD4 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.